| Oct 4 |
Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc
|
| Sep 12 |
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
|
| Sep 9 |
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
|
| Aug 24 |
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
|
| Aug 19 |
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
|
| Aug 12 |
Apogee Therapeutics files potential mixed shelf
|
| Aug 12 |
Apogee Therapeutics reports Q2 results
|
| Aug 12 |
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
|
| Aug 10 |
Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares
|
| Aug 10 |
Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE)
|
